There is no evidence that the study sample is representative of the clinical study question. It is unknown whether power calculations were used to determine the sample size. The number of patients overall, and in intervention and control group using vindesine and cisplatin (VP) was 94, 44, and 50 respectively and for cyclophosphamide, doxorubicin (Adriamycin) and cisplatin (CAP) was 93, 43, and 50 respectively.